血液悪性腫瘍(MK-1026-003)の参加者におけるネムタブルチニブ(MK-1026)の有効性と安全性
血液悪性腫瘍の参加者におけるMK-1026の有効性と安全性を評価する第2相試験
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
調査の概要
詳細な説明
This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Toll Free Number
- 電話番号:1-888-577-8839
- メール:Trialsites@msd.com
研究場所
-
-
-
Dublin、アイルランド、Dublin 9
- 募集
- Beaumont Hospital ( Site 2900)
-
コンタクト:
- Study Coordinator
- 電話番号:+35318092010
-
Limerick、アイルランド、V94 F858
- 積極的、募集していない
- University Hospital Limerick ( Site 2903)
-
-
-
-
Arkansas
-
Springdale、Arkansas、アメリカ、72762
- 募集
- Highlands Oncology Group ( Site 2728)
-
コンタクト:
- Study Coordinator
- 電話番号:479-872-8130
-
-
California
-
La Jolla、California、アメリカ、92093-0698
- 募集
- University of California San Diego Moores Cancer Center ( Site 2717)
-
コンタクト:
- Study Coordinator
- 電話番号:858-534-5201
-
Torrance、California、アメリカ、90502
- 完了
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
-
-
Colorado
-
Denver、Colorado、アメリカ、80218
- 募集
- Colorado Blood Cancer Institute ( Site 2726)
-
コンタクト:
- Study Coordinator
- 電話番号:720-754-4800
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- 完了
- The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 積極的、募集していない
- Mayo Clinic - Rochester ( Site 2706)
-
-
New Jersey
-
East Brunswick、New Jersey、アメリカ、08816
- 募集
- Astera Cancer Care ( Site 2732)
-
コンタクト:
- Study Coordinator
- 電話番号:732-672-6405
-
Hackensack、New Jersey、アメリカ、07601
- 募集
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
-
コンタクト:
- Study Coordinator
- 電話番号:551-996-3003
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58102
- 完了
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
-
コンタクト:
- Study Coordinator
- 電話番号:972-695-9450
-
-
Washington
-
Spokane、Washington、アメリカ、99208
- 募集
- Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
-
コンタクト:
- Study Coordinator
- 電話番号:509-462-2273
-
-
-
-
-
Caba、アルゼンチン、C1114AAN
- 募集
- FUNDALEU ( Site 0104)
-
コンタクト:
- Study Coordinator
- 電話番号:5411 48771046
-
Córdoba、アルゼンチン、X5016KEH
- 募集
- Hospital Privado Universitario de Córdoba ( Site 0107)
-
コンタクト:
- Study Coordinator
- 電話番号:+541569634187
-
Mendoza、アルゼンチン、M5500AYB
- 完了
- Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires、Buenos Aires、アルゼンチン、C1118AAT
- 募集
- Hospital Aleman ( Site 0102)
-
コンタクト:
- Study Coordinator
- 電話番号:+541148277000
-
-
Buenos Aires F.D.
-
Buenos Aires、Buenos Aires F.D.、アルゼンチン、C1431FWO
- 募集
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
-
コンタクト:
- Study Coordinator
- 電話番号:+541152990247
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、アルゼンチン、S2000DEJ
- 募集
- Fundacion Estudios Clinicos ( Site 0112)
-
コンタクト:
- Study Coordinator
- 電話番号:+54 0341 238 4171
-
-
-
-
-
Manchester、イギリス、M20 4BX
- 募集
- The Christie NHS Foundation Trust ( Site 2602)
-
コンタクト:
- Study Coordinator
- 電話番号:01619561217
-
-
Bristol, City of
-
Bristol、Bristol, City of、イギリス、BS2 8ED
- 募集
- Bristol Haematology and Oncology Centre ( Site 2610)
-
コンタクト:
- Study Coordinator
- 電話番号:01173426733
-
-
England
-
Nottingham、England、イギリス、NG5 1PF
- 募集
- Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
-
コンタクト:
- Study Coordinator
- 電話番号:+441159691169
-
Windsor、England、イギリス、SL4 3HD
- 募集
- GenesisCare - Windsor ( Site 2608)
-
コンタクト:
- Study Coordinator
- 電話番号:+447989474250
-
-
London, City of
-
London、London, City of、イギリス、W1G 6AD
- 募集
- Sarah Cannon Research Institute UK ( Site 2612)
-
コンタクト:
- Study Coordinator
- 電話番号:02032195234
-
-
Oxfordshire
-
Oxford、Oxfordshire、イギリス、OX4 6LB
- 募集
- GenesisCare - Oxford ( Site 2607)
-
コンタクト:
- Study Coordinator
- 電話番号:+447989474250
-
-
Suffolk
-
Newmarket、Suffolk、イギリス、CB8 7XN
- 募集
- GenesisCare - Cambridge ( Site 2611)
-
コンタクト:
- Study Coordinator
- 電話番号:01223 655145
-
-
Surrey
-
Sutton、Surrey、イギリス、SM2 5PT
- 募集
- The Royal Marsden NHS Foundation Trust. ( Site 2606)
-
コンタクト:
- Study Coordinator
- 電話番号:020 8642 6011
-
-
-
-
-
Afula、イスラエル、1834111
- 募集
- Ha Emek Medical Center ( Site 1305)
-
コンタクト:
- Study Coordinator
- 電話番号:972-46494052
-
Beersheba、イスラエル、8410101
- 募集
- Soroka Medical Center ( Site 1307)
-
コンタクト:
- Study Coordinator
- 電話番号:+97286403827
-
Haifa、イスラエル、3109601
- 募集
- Rambam Medical Center ( Site 1301)
-
コンタクト:
- Study Coordinator
- 電話番号:+97247772547
-
Jerusalem、イスラエル、9112001
- 募集
- Hadassah Ein Karem Jerusalem ( Site 1300)
-
コンタクト:
- Study Coordinator
- 電話番号:+97226778180
-
Ramat Gan、イスラエル、5262001
- 募集
- Chaim Sheba Medical Center ( Site 1302)
-
コンタクト:
- Study Coordinator
- 電話番号:+97235308401
-
Rehovot、イスラエル、76100
- 募集
- Kaplan Medical Center ( Site 1304)
-
コンタクト:
- Study Coordinator
- 電話番号:+97289441726
-
Tel Aviv、イスラエル、6423906
- 募集
- Sourasky Medical Center ( Site 1303)
-
コンタクト:
- Study Coordinator
- 電話番号:+97236973782
-
-
-
-
-
Bari、イタリア、70124
- 完了
- Istituto Tumori Giovanni Paolo II ( Site 1409)
-
Bologna、イタリア、40138
- 募集
- A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
-
コンタクト:
- Study Coordinator
- 電話番号:+390516363680
-
Brescia、イタリア、25123
- 募集
- ASST Spedali Civili di Brescia ( Site 1408)
-
コンタクト:
- Study Coordinator
- 電話番号:+39 0303996416
-
Milan、イタリア、20132
- 募集
- IRCCS Ospedale San Raffaele ( Site 1402)
-
コンタクト:
- Study Coordinator
- 電話番号:00390226434797
-
Naples、イタリア、80131
- 募集
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
-
コンタクト:
- Study Coordinator
- 電話番号:+39 0815903 382
-
Pavia、イタリア、27100
- 募集
- Fondazione IRCCS Policlinico San Matteo ( Site 1407)
-
コンタクト:
- Study Coordinator
- 電話番号:+39 0382503084
-
Reggio Emilia、イタリア、42123
- 募集
- IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
-
コンタクト:
- Study Coordinator
- 電話番号:+39 0522295654
-
Roma、イタリア、00161
- 完了
- Policlinico Umberto I ( Site 1404)
-
-
-
-
-
Kyiv、ウクライナ、03022
- 募集
- National Cancer Institute ( Site 2507)
-
コンタクト:
- Study Coordinator
- 電話番号:+380672091427
-
-
Cherkasy Oblast
-
Cherkassy、Cherkasy Oblast、ウクライナ、18009
- 積極的、募集していない
- MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk、Ivano-Frankivsk Oblast、ウクライナ、76008
- 完了
- Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
-
-
Lviv Oblast
-
Lviv、Lviv Oblast、ウクライナ、79044
- 募集
- Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
-
コンタクト:
- Study Coordinator
- 電話番号:+380322352276
-
-
-
-
New South Wales
-
Sydney、New South Wales、オーストラリア、2747
- 完了
- Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
-
-
Victoria
-
Box Hill、Victoria、オーストラリア、3128
- 募集
- Box Hill Hospital ( Site 0203)
-
コンタクト:
- Study Coordinator
- 電話番号:+611300342255
-
-
Western Australia
-
Nedlands、Western Australia、オーストラリア、6009
- 募集
- Sir Charles Gairdner Hospital ( Site 0200)
-
コンタクト:
- Study Coordinator
- 電話番号:+61864573333
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 5G2
- 募集
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
-
コンタクト:
- Study Coordinator
- 電話番号:4035213723
-
-
Ontario
-
Ottawa、Ontario、カナダ、K1H 8L6
- 募集
- The Ottawa Hospital ( Site 0404)
-
コンタクト:
- Study Coordinator
- 電話番号:613 737-7700
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
-
コンタクト:
- Study Coordinator
- 電話番号:416-946-2827
-
-
Quebec
-
Montreal、Quebec、カナダ、H3T 1E2
- 募集
- Jewish General Hospital ( Site 0400)
-
コンタクト:
- Study Coordinator
- 電話番号:5143408222 x 24572
-
Montreal、Quebec、カナダ、H1T 2M4
- 募集
- CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
-
コンタクト:
- Study Coordinator
- 電話番号:5142523400
-
-
-
-
Canton Ticino
-
Bellinzona、Canton Ticino、スイス、6500
- 募集
- Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
-
コンタクト:
- Study Coordinator
- 電話番号:+41918118540
-
-
Canton of Bern
-
Bern、Canton of Bern、スイス、3010
- 募集
- Inselspital Bern ( Site 2303)
-
コンタクト:
- Study Coordinator
- 電話番号:+41316329023
-
-
-
-
-
Alicante、スペイン、03010
- 募集
- Hospital General Universitario de Alicante ( Site 2007)
-
コンタクト:
- Study Coordinator
- 電話番号:965 93 30 00
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitari Vall d'Hebron ( Site 2001)
-
コンタクト:
- Study Coordinator
- 電話番号:+34934893806
-
Madrid、スペイン、28041
- 募集
- Hospital Universitario 12 de Octubre ( Site 2003)
-
コンタクト:
- Study Coordinator
- 電話番号:+34917792809
-
Madrid、スペイン、28222
- 募集
- Hospital Puerta de Hierro ( Site 2009)
-
コンタクト:
- Study Coordinator
- 電話番号:+34911916000
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、スペイン、08908
- 募集
- Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
-
コンタクト:
- Study Coordinator
- 電話番号:+34932607750
-
-
Castille and León
-
Salamanca、Castille and León、スペイン、37007
- 募集
- Hospital Universitario de Salamanca ( Site 2002)
-
コンタクト:
- Study Coordinator
- 電話番号:34923 29 11 00x55974
-
-
La Coruna
-
A Coruña、La Coruna、スペイン、15006
- 募集
- CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
-
コンタクト:
- Study Coordinator
- 電話番号:34981178000
-
-
-
-
-
Hradec Králové、チェコ、500 05
- 募集
- Fakultni nemocnice Hradec Kralove ( Site 0601)
-
コンタクト:
- Study Coordinator
- 電話番号:+420495832159
-
-
Brno-mesto
-
Brno、Brno-mesto、チェコ、625 00
- 募集
- Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
-
コンタクト:
- Study Coordinator
- 電話番号:+420532233642
-
-
-
-
Central Jutland
-
Aarhus N、Central Jutland、デンマーク、8200
- 完了
- Aarhus University Hospital ( Site 0702)
-
-
North Denmark
-
Aalborg、North Denmark、デンマーク、9000
- 募集
- Aalborg Universitetshospital ( Site 0703)
-
コンタクト:
- Study Coordinator
- 電話番号:+45 97660000
-
-
Region Sjælland
-
Koege、Region Sjælland、デンマーク、4600
- 募集
- Sjællands Universitetshospital Køge ( Site 0701)
-
コンタクト:
- Study Coordinator
- 電話番号:+45 46323200
-
-
Region Syddanmark
-
Odense C、Region Syddanmark、デンマーク、5000
- 完了
- Odense University Hospital ( Site 0705)
-
-
-
-
-
Ankara、トルコ(Türkiye)、06590
- 募集
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
-
コンタクト:
- Study Coordinator
- 電話番号:+903125957099
-
Istanbul、トルコ(Türkiye)、34365
- 完了
- VKV Amerikan Hastanesi ( Site 2403)
-
Istanbul、トルコ(Türkiye)、34381
- 募集
- Sisli Florence Nightingale Hastanesi ( Site 2407)
-
コンタクト:
- Study Coordinator
- 電話番号:+90 542 502 50 75
-
Izmir、トルコ(Türkiye)、35340
- 積極的、募集していない
- Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
-
-
Istanbul
-
Stanbul、Istanbul、トルコ(Türkiye)、34214
- 積極的、募集していない
- Mega Medipol-Hematology ( Site 2406)
-
-
-
-
Baden-Wurttemberg
-
Ulm、Baden-Wurttemberg、ドイツ、89081
- 募集
- Universitaetsklinikum Ulm. ( Site 0906)
-
コンタクト:
- Study Coordinator
- 電話番号:+ 49 731 500 45901
-
-
North Rhine-Westphalia
-
Cologne、North Rhine-Westphalia、ドイツ、50937
- 募集
- Universitaetsklinikum Koeln ( Site 0901)
-
コンタクト:
- Study Coordinator
- 電話番号:+4922147897046
-
Siegen、North Rhine-Westphalia、ドイツ、57072
- 完了
- St. Marien-Krankenhaus Siegen ( Site 0914)
-
-
Saxony
-
Dresden、Saxony、ドイツ、01307
- 募集
- Universitaetsklinikum Carl Gustav Carus ( Site 0902)
-
コンタクト:
- Study Coordinator
- 電話番号:0049 351 458 5692
-
-
-
-
-
Budapest、ハンガリー、1122
- 募集
- Orszagos Onkologiai Intezet ( Site 1200)
-
コンタクト:
- Study Coordinator
- 電話番号:+3612248600
-
-
Baranya
-
Pécs、Baranya、ハンガリー、7624
- 募集
- Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
-
コンタクト:
- Study Coordinator
- 電話番号:+3672536000
-
-
Hajdú-Bihar
-
Debrecen、Hajdú-Bihar、ハンガリー、4032
- 募集
- Debreceni Egyetem Klinikai Kozpont ( Site 1201)
-
コンタクト:
- Study Coordinator
- 電話番号:+3652255196
-
-
Szabolcs-Szatmár-Bereg
-
Nyíregyháza、Szabolcs-Szatmár-Bereg、ハンガリー、4400
- 募集
- Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
-
コンタクト:
- Study Coordinator
- 電話番号:+3642599700
-
-
-
-
-
Paris、フランス、75010
- 募集
- Hopital Saint Louis ( Site 0805)
-
コンタクト:
- Study Coordinator
- 電話番号:+33142499236
-
-
Alpes-Maritimes
-
Nice、Alpes-Maritimes、フランス、06202
- 募集
- Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
-
コンタクト:
- Study Coordinator
- 電話番号:+33 4 92 03 57 85
-
-
Auvergne-Rhône-Alpes
-
Pierre-Bénite、Auvergne-Rhône-Alpes、フランス、69495
- 募集
- Centre Hospitalier Lyon-Sud ( Site 0804)
-
コンタクト:
- Study Coordinator
- 電話番号:+33478864348
-
-
Bouches-du-Rhone
-
Marseille、Bouches-du-Rhone、フランス、13009
- 募集
- Institut Paoli-Calmettes ( Site 0803)
-
コンタクト:
- Study Coordinator
- 電話番号:+33491223537
-
-
Yvelines
-
Le Chesnay、Yvelines、フランス、78150
- 完了
- Centre Hospitalier de Versailles ( Site 0809)
-
-
-
-
-
Rio de Janeiro、ブラジル、20231-050
- 募集
- Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
-
コンタクト:
- Study Coordinator
- 電話番号:+552132076564
-
São Paulo、ブラジル、01321-001
- 募集
- Hospital Paulistano - Amil Clinical Research ( Site 0311)
-
コンタクト:
- Study Coordinator
- 電話番号:+551130161340
-
São Paulo、ブラジル、01321-001
- 積極的、募集していない
- BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
-
-
São Paulo
-
São Paulo、São Paulo、ブラジル、05403-000
- 募集
- Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
-
コンタクト:
- Study Coordinator
- 電話番号:551145737543
-
-
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、30-727
- 募集
- Pratia MCM Krakow ( Site 1601)
-
コンタクト:
- Study Coordinator
- 電話番号:48 12 2954135
-
-
Lower Silesian Voivodeship
-
Wroclaw、Lower Silesian Voivodeship、ポーランド、50-367
- 完了
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、ポーランド、02-781
- 募集
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
-
コンタクト:
- Study Coordinator
- 電話番号:+48225462223
-
-
Opole Voivodeship
-
Opole、Opole Voivodeship、ポーランド、45-061
- 完了
- Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
-
-
Pomeranian Voivodeship
-
Gdynia、Pomeranian Voivodeship、ポーランド、81-519
- 完了
- Szpitale Pomorskie Sp. z o.o. ( Site 1600)
-
-
-
-
-
Brasov、ルーマニア、500052
- 募集
- Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
-
コンタクト:
- Study Coordinator
- 電話番号:0729075567
-
Iași、ルーマニア、700483
- 募集
- Institutul Regional de Oncologie Iasi ( Site 1801)
-
コンタクト:
- Study Coordinator
- 電話番号:40374278811
-
-
Bucharest
-
Bucharest、Bucharest、ルーマニア、030171
- 募集
- Spitalul Clinic Colțea ( Site 1805)
-
コンタクト:
- Study Coordinator
- 電話番号:0040213874100
-
-
Constanța County
-
Ovidiu、Constanța County、ルーマニア、905900
- 完了
- Ovidius Clinical Hospital ( Site 1804)
-
-
-
-
Anhui
-
Hefei、Anhui、中国、230071
- 積極的、募集していない
- Anhui Provincial Hospital ( Site 2808)
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100191
- 募集
- Peking University Third Hospital-Hematology ( Site 2827)
-
コンタクト:
- Study Coordinator
- 電話番号:010-82266699
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400072
- 積極的、募集していない
- The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- 積極的、募集していない
- Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
-
-
Guangxi
-
Liuzhou、Guangxi、中国、545006
- 募集
- Liuzhou People's Hospital ( Site 2817)
-
コンタクト:
- Study Coordinator
- 電話番号:+8607722662950
-
Nanning、Guangxi、中国、530028
- 募集
- Guangxi Medical University Cancer Hospital ( Site 2814)
-
コンタクト:
- Study Coordinator
- 電話番号:+8607715323174
-
-
Henan
-
Zhengzhou、Henan、中国、450008
- 募集
- Henan Cancer Hospital-hematology department ( Site 2802)
-
コンタクト:
- Study Coordinator
- 電話番号:0371-65588007
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- 募集
- Wuhan Union Hospital ( Site 2816)
-
コンタクト:
- Study Coordinator
- 電話番号:+8618627091655
-
-
Hunan
-
Changsha、Hunan、中国、410011
- 募集
- The Second Xiangya Hospital of Central South University ( Site 2820)
-
コンタクト:
- Study Coordinator
- 電話番号:+8613975806137
-
Changsha、Hunan、中国、410013
- 募集
- Hunan Cancer Hospital ( Site 2822)
-
コンタクト:
- Study Coordinator
- 電話番号:0731-88651669
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210029
- 募集
- Jiangsu Province Hospital ( Site 2823)
-
コンタクト:
- Study Coordinator
- 電話番号:025-86211033
-
Xuzhou、Jiangsu、中国、221000
- 完了
- The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- 募集
- The First Affiliated Hospital of Nanchang University ( Site 2815)
-
コンタクト:
- Study Coordinator
- 電話番号:13970038386
-
-
Jilin
-
Changchun、Jilin、中国、130021
- 募集
- The First Hospital of Jilin University-Hematology ( Site 2803)
-
コンタクト:
- Study Coordinator
- 電話番号:0431-88786014
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 募集
- Fudan University Shanghai Cancer Center ( Site 2801)
-
コンタクト:
- Study Coordinator
- 電話番号:+8602164175590
-
Shanghai、Shanghai Municipality、中国、200040
- 募集
- Huashan Hospital, Fudan University ( Site 2821)
-
コンタクト:
- Study Coordinator
- 電話番号:021-52889999
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- 募集
- West China Hospital Sichuan University ( Site 2810)
-
コンタクト:
- Study Coordinator
- 電話番号:+86028-85422114
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、301617
- 募集
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
-
コンタクト:
- Study Coordinator
- 電話番号:+8615900265415
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310002
- 募集
- The First Affiliated Hospital, Zhejiang University ( Site 2826)
-
コンタクト:
- Study Coordinator
- 電話番号:057187236114
-
-
-
-
-
Seoul、韓国、03722
- 募集
- Severance Hospital Yonsei University Health System ( Site 2201)
-
コンタクト:
- Study Coordinator
- 電話番号:+82222281972
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center ( Site 2200)
-
コンタクト:
- Study Coordinator
- 電話番号:+82234106548
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
- Has a life expectancy of at least 3 months, based on the investigator assessment
- Has the ability to swallow and retain oral medication
- Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
- Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
- Has adequate organ function
- Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
- Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
- Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART
Part 1 and Part 2 (Cohorts A to C and J)
-
Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with
- At least 2 lines of prior therapy (Part 1 only)
- Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines
- Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive
- Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy
- Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J
- Has active disease for CLL/SLL clearly documented to initiate therapy
- For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)
Part 2 (Cohorts D to G)
- Has a confirmed diagnosis of and meets the following prior therapy requirements:
- Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)
- Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)
- Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen
- Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)
- Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan
- Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening
Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi
- Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease
- Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%
- Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival
Exclusion Criteria:
- Has active HBV/HCV infection (Part 1 and Part 2)
- Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
- Has active central nervous system (CNS) disease
- Has an active infection requiring systemic therapy
- Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
- Has any clinically significant gastrointestinal abnormalities that might alter absorption
- History of severe bleeding disorders
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Nemtabrutinib
Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation. |
Nemtabrutinib tablets administered orally QD.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
時間枠:Up to ~56 days (Cycles 1-2, cycle = 28 days)
|
DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting >7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for >1 week (with exceptions); missing >25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity. |
Up to ~56 days (Cycles 1-2, cycle = 28 days)
|
|
Part 1: Number of participants experiencing adverse events (AEs)
時間枠:Up to ~71 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1. |
Up to ~71 months
|
|
Part 1: Number of participants discontinuing study treatment due to AEs
時間枠:Up to ~42 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1. |
Up to ~42 months
|
|
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
時間枠:Up to ~61 months
|
ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~61 months
|
|
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
時間枠:Up to ~61 months
|
ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography [CT]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters [SPD] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities. |
Up to ~61 months
|
|
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
時間枠:Up to ~71 months
|
ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal). |
Up to ~71 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Area Under the Curve (AUC) of Nemtabrutinib
時間枠:At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
時間枠:At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
時間枠:At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
時間枠:Up to ~71 months
|
ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~71 months
|
|
Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
時間枠:Up to ~71 months
|
For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~71 months
|
|
Part 2: Number of participants experiencing AEs
時間枠:Up to ~61 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2. |
Up to ~61 months
|
|
Part 2: Number of participants discontinuing study treatment due to AEs
時間枠:Up to ~42 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2. |
Up to ~42 months
|
|
Part 2: AUC of Nemtabrutinib
時間枠:At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: Cmin of Nemtabrutinib
時間枠:At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: Cmax of Nemtabrutinib
時間枠:At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
時間枠:Up to ~61 months
|
For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~61 months
|
|
Part 2: DOR per Lugano criteria 2014 as assessed by ICR
時間枠:Up to ~61 months
|
For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities. |
Up to ~61 months
|
|
Part 2: DOR per IWWM criteria 2014 as assessed by ICR
時間枠:Up to ~61 months
|
For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal). |
Up to ~61 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Medical Director、Merck Sharp & Dohme LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 1026-003
- MK-1026-003 (その他の識別子:MSD)
- 2020-002324-36 (EudraCT番号)
- U1111-1290-4004 (レジストリ識別子:UTN)
- 2023-504931-42-00 (レジストリ識別子:EU CT)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。